Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]MK-1084 (Calderasib) in Healthy Adults
NCT06687759Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of calderasib in cancer, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to Last and 19 more. Started Jun 2024; status: completed.
02
Drugs
calderasib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06687759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687759.